Novo Nordisk’s US Public Affairs Head Jennifer Duck Departs

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

“This one detail mattered,” said an insider close to Jennifer Duck, as Novo Nordisk’s U.S. Public Affairs Head departed amid corporate restructuring, according to a report from ETHealthworld on February 10, 2023.

Jennifer Duck, who led the U.S. public affairs team at Novo Nordisk, has left her position, marking a significant change in the company’s leadership. The move happens as Novo Nordisk undergoes a broader restructuring effort aimed at optimizing its operations and improving its market competitiveness. On February 10, 2023, ETHealthworld first reported Duck’s departure.
Duck’s exit comes after she spent nearly 5 years at the company, during which time she played a crucial role in shaping Novo Nordisk’s public policy and government affairs strategy in the United States. The Danish multinational pharmaceutical company has been adjusting to an evolving healthcare landscape, with increasing scrutiny on pharmaceutical pricing and regulatory requirements.

1. Novo Nordisk had previously announced a global restructuring plan, which includes reducing its workforce by approximately 1,000 to 1,300 employees.
2. The company has also invested around $2 billion annually in research and development to expand its portfolio of diabetes and obesity treatments.
3. As part of its efforts to improve operational efficiency, Novo Nordisk will be reducing its global workforce, primarily affecting its headquarters and other administrative functions.

The restructuring aims to ensure the long-term sustainability and competitiveness of the company. “We are taking necessary steps to ensure our organization is fit for the future,” said a spokesperson from Novo Nordisk, based in Plainsboro, New Jersey. As the company navigates this ******* of change, it continues to prioritize its core business areas and maintain its commitment to delivering innovative treatments to patients.
The departure of key figures like Duck might signal further adjustments within the company. What happens next will depend on how effectively Novo Nordisk can execute its restructuring plan while maintaining its market position and continuing to serve the needs of its customers.

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up